

Hepatitis C Virus Envelope Protein E2 Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

<https://marketpublishers.com/r/HBA7C985D199EN.html>

Date: October 2022

Pages: 35

Price: US\$ 3,500.00 (Single User License)

ID: HBA7C985D199EN

Abstracts

Hepatitis C Virus Envelope Protein E2 Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

SUMMARY

Hepatitis C Virus Envelope Protein E2 pipeline Target constitutes close to 10 molecules. Out of which approximately 5 molecules are developed by companies and remaining by the universities/institutes. The latest report Hepatitis C Virus Envelope Protein E2 - Drugs In Development, 2022, outlays comprehensive information on the Hepatitis C Virus Envelope Protein E2 targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.

Hepatitis C Virus Envelope Protein E2 - E2 is a viral structural protein found in the hepatitis C virus. It is present on the viral membrane and functions as a host receptor binding protein mediating entry into host cells. It is an important target for the design of entry inhibitors and vaccine immunogens. The molecules developed by companies in Phase II and Preclinical stages are 1 and 4 respectively. Similarly, the universities portfolio in Preclinical and Discovery stages comprises 3 and 2 molecules, respectively. Report covers products from therapy areas Infectious Disease which include indications Hepatitis C.

Furthermore, this report also reviews key players involved in Hepatitis C Virus Envelope Protein E2 targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary

databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

The report provides a snapshot of the global therapeutic landscape for Hepatitis C Virus Envelope Protein E2

The report reviews Hepatitis C Virus Envelope Protein E2 targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in Hepatitis C Virus Envelope Protein E2 targeted therapeutics and enlists all their major and minor projects

The report assesses Hepatitis C Virus Envelope Protein E2 targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news and deals related to Hepatitis C Virus Envelope Protein E2 targeted therapeutics

REASONS TO BUY

Gain strategically significant competitor information, analysis, and insights to

formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand the targeted therapy areas and indications for Hepatitis C Virus Envelope Protein E2
Identify the use of drugs for target identification and drug repurposing

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Hepatitis C Virus Envelope Protein E2 development landscape

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Contents

Introduction

Global Markets Direct Report Coverage

Hepatitis C Virus Envelope Protein E2 - Overview

Hepatitis C Virus Envelope Protein E2 - Therapeutics Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Products under Development by Universities/Institutes

Hepatitis C Virus Envelope Protein E2 - Therapeutics Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Hepatitis C Virus Envelope Protein E2 - Companies Involved in Therapeutics Development

Center for Genetic Engineering and Biotechnology

Ennaid Therapeutics LLC

Integrated BioTherapeutics Inc

Toray Industries Inc

Uvax Bio LLC

Hepatitis C Virus Envelope Protein E2 - Drug Profiles

CIGB-230 - Drug Profile

Product Description

Mechanism Of Action

Hepatitis C (HCV) - Drug Profile

Product Description

Mechanism Of Action

History of Events

hepatitis C (strain H77) vaccine - Drug Profile

Product Description

Mechanism Of Action

hepatitis C vaccine - Drug Profile

Product Description

Mechanism Of Action

hepatitis C vaccine - Drug Profile

Product Description

Mechanism Of Action

hepatitis C vaccine - Drug Profile

Product Description

Mechanism Of Action

History of Events

Monoclonal Antibodies to Inhibit E2 Glycoprotein for HCV - Drug Profile

Product Description

Mechanism Of Action

History of Events

Monoclonal Antibodies to Target Viral E1 and E2 Proteins for Hepatitis C - Drug Profile

Product Description

Mechanism Of Action

Monoclonal Antibody to Inhibit E1 and E2 Glycoprotein for Hepatitis C - Drug Profile

Product Description

Mechanism Of Action

History of Events

Synthetic Peptides to Inhibit E1 and E2 Glycoprotein for HCV - Drug Profile

Product Description

Mechanism Of Action

History of Events

Hepatitis C Virus Envelope Protein E2 - Dormant Products

Hepatitis C Virus Envelope Protein E2 - Discontinued Products

Hepatitis C Virus Envelope Protein E2 - Product Development Milestones

Featured News & Press Releases

Jun 10, 2013: IBT and Stanford Awarded STTR

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List Of Tables

LIST OF TABLES

Number of Products under Development by Stage of Development, 2022
Number of Products under Development by Therapy Areas, 2022
Number of Products under Development by Indication, 2022
Number of Products under Development by Companies, 2022
Products under Development by Companies, 2022
Number of Products under Investigation by Universities/Institutes, 2022
Products under Investigation by Universities/Institutes, 2022
Number of Products by Stage and Mechanism of Actions, 2022
Number of Products by Stage and Route of Administration, 2022
Number of Products by Stage and Molecule Type, 2022
Pipeline by Center for Genetic Engineering and Biotechnology, 2022
Pipeline by Ennaid Therapeutics LLC, 2022
Pipeline by Integrated BioTherapeutics Inc, 2022
Pipeline by Toray Industries Inc, 2022
Pipeline by Uvax Bio LLC, 2022
Dormant Projects, 2022
Discontinued Products, 2022

List Of Figures

LIST OF FIGURES

Number of Products under Development by Stage of Development, 2022

Number of Products by Stage and Mechanism of Actions, 2022

Number of Products by Routes of Administration, 2022

Number of Products by Stage and Routes of Administration, 2022

Number of Products by Molecule Types, 2022

Number of Products by Stage and Molecule Types, 2022

I would like to order

Product name: Hepatitis C Virus Envelope Protein E2 Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

Product link: <https://marketpublishers.com/r/HBA7C985D199EN.html>

Price: US\$ 3,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/HBA7C985D199EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

